LTD

Inheritance, Dreams, Future - The Successful Holding of the 2nd HUAPOP Creative Festival in Shenzhen in 2024

Retrieved on: 
Sunday, March 31, 2024
Belt, Southern University, LTD, HUA, Associate, Rejuvenation, Dream, Civilization, Party, Federation, Dafen, Tourism

Shenzhen, China--(Newsfile Corp. - March 31, 2024) - The 2nd HUAPOP Creative Festival with the theme of "Inheritance, Dreams, Future" was held in the forefront city of Shenzhen, a hub of reform, openness, and fashion, on March 26, 2024.

Key Points: 
  • Shenzhen, China--(Newsfile Corp. - March 31, 2024) - The 2nd HUAPOP Creative Festival with the theme of "Inheritance, Dreams, Future" was held in the forefront city of Shenzhen, a hub of reform, openness, and fashion, on March 26, 2024.
  • The festival, organized by the HUAPOP Creative Festival Organizing Committee, aims to promote and showcase the creative achievements of the "HUA" culture from 2022-2023, and to promote and lead the new trend of global "HUAPOP."
  • The 2nd HUAPOP Creative Festival, jointly organized by the HUAPOP Creative Festival Organizing Committee, HUAPOP Industrial Economic Research Institute, National Base For International Cultural Trade (Shenzhen), and 36Kr, has been planned and prepared for nearly 10 months.
  • The 2nd HUAPOP Creative Festival continues the format of "rankings" and selects the HUAPOP Creative Ranking, HUAPOP Popularity Ranking, HUAPOP Institutional Ranking, and HUAPOP City Index.

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, X-ray, LTD, Cardiology, Patient, Science, Radiology, SCL, Department of Tourism (Philippines), NANO, Teleradiology, ARC, Marketing, Medical device

PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).

Key Points: 
  • Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
  • The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
  • The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
  • “We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.

Global Technologies, LTD Closes on the Sale of Its Commercial Property in Georgia

Retrieved on: 
Wednesday, April 3, 2024
OTC Markets Group, LTD, Sale, Acquisition

Parsippany, NJ, April 03, 2024 (GLOBE NEWSWIRE) -- Global Technologies Ltd. (OTC Pink:GTLL) (the “Company” or “Global”) a company with operations in the acquisition and redevelopment of distressed properties and customer sales management is pleased to announce that it has closed on the sale of its commercial building located in Sylvester, GA.

Key Points: 
  • Parsippany, NJ, April 03, 2024 (GLOBE NEWSWIRE) -- Global Technologies Ltd. (OTC Pink:GTLL) (the “Company” or “Global”) a company with operations in the acquisition and redevelopment of distressed properties and customer sales management is pleased to announce that it has closed on the sale of its commercial building located in Sylvester, GA.
    On March 26, 2024, the Company closed on the sale of its commercial building, which was part of the Foxx Trot Tango purchase that took place in June of 2023.
  • The net funds received by the Company will be utilized for operational expenses to help further support and advance both operating businesses: 10 Fold Services and GOe3.
  • Fredrick K. Cutcher, CEO of Global Technologies, LTD, stated “The sale of our commercial property serves as yet another successful transaction that we have been able to deliver upon early on in 2024.
  • The net funds available from the sale of this property will be instrumental for us to continue on a path of success for both 10 Fold Services and GOe3, as we move into the next quarter of 2024 and beyond.” Mr. Cutcher continued, “This year has started off on a very positive note for us with the closing of the GOe3 acquisition and the expansion of the 10 Fold Services operations.”
    The Company looks forward to providing shareholders with additional updates on operations in the near future.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, PIN, LTD, Intermountain Health, Radiology, Exercise, Medical imaging, Patient, Health, Fatty liver disease, Action Replay, Policy, Sale, AI, D&O, Google Images, Teleradiology, NANO, GAAP, ARC, Depreciation, Marketing, FDA, Vertebral compression fracture, Hand, Cryptocurrency

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 29, 2024
AEON, Steps, U.S. FDA, LTD, Headache, Patient, Migraine, Investment, Alembic Pharmaceuticals, Safety, FDA, Food, Pharmaceutical industry

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • We are now well-positioned to plan for the initiation of our pivotal Phase 3 program,” commented Marc Forth, AEON’s President and Chief Executive Officer.
  • “Recently, we announced plans to conduct an interim analysis of our ongoing Phase 2 study of ABP-450 as a preventive treatment for chronic migraine, which completed enrollment in December 2023.
  • On track to announce topline results from the Phase 2 study of ABP-450 as a preventive treatment for chronic migraine in the third quarter of 2024.
  • Episodic Migraine Program Next Steps – The Company is continuing to plan for the initiation of its proposed pivotal Phase 3 program for ABP-450.

Data Center World’s Expo Hall to Feature Hundreds of Innovative Products and Services Data Center Facilities and IT Professionals Need to Know to Plan, Manage and Optimize Data Centers

Retrieved on: 
Monday, April 8, 2024
Networks, Internet, Data Management, Technology, Software, Transfer, LTD, Transport, Carbon, HVAC, Starline, HTF, Cavitation, Virginia Transformer Corporation, Network throughput, Vertiv, MVA, Exhibition, Safety, DCIM, Fiber, Electricity, Control, Server Technology, DLC, GIGABYTE, PEAK, AI, Fluid mechanics, Network, Expo Hall, Gesellschaft mit beschränkter Haftung, Energy, GWP, Mining, Immersion, Corrosion engineering, Temperature, CPI, Hybrid, Recycling, HPC, Corrosion, Data center, DDC, Peak (automotive products), Business analyst, Dell

Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.

Key Points: 
  • Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.
  • The technologies will provide data center facilities and IT professionals with all the information they need to plan, manage and optimize their data centers.
  • Data Center World is AFCOM’s annual gathering of IT and data center professionals.
  • Future-proof your data center with hybrid liquid-air cooling, intelligent power handling, and enterprise environment controls by DDC’s DCIM monitoring software.

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters

Retrieved on: 
Monday, March 25, 2024
LTD, Y90, Patient, PLLC, Hospital, Research, Cancer, Telehealth, Radiopharmaceutical, Life expectancy, CPT, Liver cancer, ISO, Physician, Health

TeleDaaS is launching a pilot program and enrolling early adopters.

Key Points: 
  • TeleDaaS is launching a pilot program and enrolling early adopters.
  • By eliminating inefficient workflows, TeleDaaS saves time for physicians and helps hospitals improve their revenue capture under existing CPT codes.
  • "With this new service, we are elevating healthcare by providing dosimetry services directly to hospitals,” said TeleDaaS Chief Medical Officer Dr. Mark Crockett, M.D.
  • TeleDaaS is designed to provide highly-scalable, best-in-class dosimetry services that integrate with existing imaging workflows, to transform cancer treatment research and development and treatment planning.

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Retrieved on: 
Tuesday, March 19, 2024
AEON, Private placement, Private, LTD, FPA, Sale, Migraine, Note, Alembic Pharmaceuticals, AB toxin, Food, FDA, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AMEX: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the “Investment Amount”) aggregate principal amount of senior secured convertible notes (the "Notes") with Daewoong Pharmaceutical Co., LTD. Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements. The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024. Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes. Upon funding of the second installment of the Investment Amount, the Company will appoint one designee of Daewoong to the AEON Board of Directors, subject to a customary due diligence process by AEON. The Daewoong designee must be a member of Daewoong’s senior management team.

Key Points: 
  • Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements.
  • The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024.
  • Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes.
  • Concurrent with the execution of the agreements for the Private Placement, the Company terminated its forward purchase agreements (each an “FPA” and the counterparties thereto, together, the “FPA Providers”).

Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024

Retrieved on: 
Monday, March 18, 2024
Event, Interest, LTD, NANO

PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.

Key Points: 
  • PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.
  • Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m.
  • Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration .
  • You may access the live webcast of the conference call by using the following link: Nanox Q4 Earnings Call Webcast .

Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold

Retrieved on: 
Tuesday, March 12, 2024
Syndrome, Health, National Health Service, ROI, Congress, LTD, Rheumatology, Bone disease, Data analysis, Risk, Patient, Fracture, VCF, NHS, Abdomen, Hospital, Research, AI, University, Systematic review, Treatment, Spine, FLS, Family, FDA, Vertebral compression fracture, University of Oxford, Medical device

PETACH TIKVA, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd. (Nanox.AI), today announced that early findings from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at National Health Services (NHS) hospitals in the UK, which include University of Oxford and other healthcare centers.

Key Points: 
  • Thus far in the study, the Nanox.AI algorithm has identified over 2,400 patients with VCF from routine CT scans that were not known to the NHS’s hospitals, and have since been flagged for follow-up assessments.
  • “Leveraging AI-powered population health solutions presents an effective and efficient avenue for early identification of patients at very high risk of fractures, facilitating timely intervention and care.
  • As such, there have been efforts to introduce FLS into public health systems.
  • The next-generation HealthOST received FDA 510(K) clearance in April 2022.